Business Context and Reporting Period
Company: Organogenesis Holdings Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 7, 2026
Reporting Period: Fiscal First Quarter ended March 31, 2026
Context: The filing announces the release of financial results for the quarter ended March 31, 2026, via a press release incorporated by reference as Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text serves as a cover document referencing a press release (Exhibit 99.1) for detailed financial data. The filing text itself does not provide clear values for the following metrics:
- Revenue
- Profit (Net Income/Loss)
- Cash Flow
- Margins
- Debt Levels
- Liquidity Position
Material Changes
The filing text does not contain specific data regarding material changes in financial performance compared to the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for year-over-year or quarter-over-quarter comparisons.
Guidance, Outlook, and Risks
Guidance and Outlook: The filing text does not contain specific forward-looking guidance, management commentary, or outlook statements.
Risks and Contingencies: No specific risks or contingencies are detailed in the body of this 8-K filing.
Unusual Items: No unusual items are described in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 7, 2026) for actual revenue, earnings, and cash flow figures.
- Verify year-over-year growth rates and margin trends in the press release.
- Check for any updated financial guidance or operational outlook provided in the press release.
- Confirm the status of the company's liquidity and debt obligations as detailed in the full earnings release.